Literature DB >> 11051274

Gene therapy in experimental autoimmune encephalomyelitis.

P M Mathisen1, V K Tuohy.   

Abstract

Gene therapy traditionally has been associated with "gene replacement." where exogenous recombinant DNA is introduced ex vivo into somatic cells that are then introduced back into the patient as a way to correct an inherited genetic defect. However, several novel gene therapy strategies for treating autoimmune diseases recently have emerged. Strategies involving the use of several types of DNA vaccines, the application of various viral vectors, and the use of diverse cellular vectors have shown promise in inhibiting autoimmune-mediated inflammation and repairing tissue damaged as a result of autoimmune attack. In the current review, we examine and discuss the development and proposed use of emerging gene therapy strategies for the treatment of autoimmune disease with specific emphasis on experimental autoimmune encephalomyelitis (EAE), an animal model widely used in multiple sclerosis (MS) research.

Entities:  

Mesh:

Year:  2000        PMID: 11051274     DOI: 10.1023/a:1006625412367

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  56 in total

1.  Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells.

Authors:  M A Chattergoon; T M Robinson; J D Boyer; D B Weiner
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

2.  Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis.

Authors:  J L Croxford; J K O'Neill; R R Ali; K Browne; A P Byrnes; M J Dallman; M J Wood; M Fedlmann; D Baker
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

3.  Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis.

Authors:  A A Vandenbark; G Hashim; H Offner
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

4.  A role for platelet-derived growth factor in normal gliogenesis in the central nervous system.

Authors:  W D Richardson; N Pringle; M J Mosley; B Westermark; M Dubois-Dalcq
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

Review 5.  Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.

Authors:  L Steinman
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

6.  Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.

Authors:  A Lobell; R Weissert; S Eltayeb; C Svanholm; T Olsson; H Wigzell
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

7.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

8.  Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  V K Tuohy; M Yu; L Yin; J A Kawczak; R P Kinkel
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

9.  Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination.

Authors:  R Furlan; P L Poliani; F Galbiati; A Bergami; L M Grimaldi; G Comi; L Adorini; G Martino
Journal:  Hum Gene Ther       Date:  1998-11-20       Impact factor: 5.695

10.  Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.

Authors:  B L McRae; C L Vanderlugt; M C Dal Canto; S D Miller
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  1 in total

1.  The effects of intradermal vaccination with DNA encoding for the T-cell receptor on the induction of experimental autoimmune encephalomyelitis in B10.PL mice.

Authors:  Soon Seog Kwon; Nachsung Kim; Tae-June Yoo
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.